Mynewsdesk LinkedIn
Press & News

The next generation biopharmaceuticals

Press releases 2019

Older press releases

2019-09-23

Affibody Relocates to the Karolinska Institute Campus in Solna

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi- and multi-specific drug projects, today announced its relocation to the Karolinska Institute Campus in Solna.[read more]

2019-09-20

Affibody and GE Healthcare to Collaborate on Development of Affibody® PET Imaging Tracers

Solna, Sweden, September 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced a strategic collaboration with GE Healthcare to develop and commercialize Affibody®-based PET imaging tracers, with initial focus...[read more]

2019-08-23

Interim Report – January to June 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter of 2019.[read more]

« Older press releases

Affibodys latest Press releases

2021-06-02

Notice to attend Annual General Meeting

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby given notice...[read more]

Press & News

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

About Affibody

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)

Investor information